43 / 52
43
Oftalmopatía De Graves En Edad Pediátrica. Revisión De La Literatura Y Reporte De 5 Casos
BIBLIOGRAFÍA
1.
Eha, J., Pitz, S., & Pohlenz, J. (2010). Clinical
features of pediatric Graves’ orbitopathy.
International Ophthalmology, 30(6), 717–721.
2.
Krassas, G. E., Segni, M., & Wiersinga, W. M.
(2005). Childhood Graves’ ophthalmopathy:
results of a European questionnaire study.
European Journal of Endocrinology, 153(4),
515–521.
3.
Bartalena, L., Pinchera, A., & Marcocci, C. (2000).
Management of Graves’ ophthalmopathy: reality
and perspectives. Endocrine Reviews, 21(2),
168–199.
4.
Smith, T. J., & Hegedüs, L. (2016). Graves’
Disease. New England Journal of Medicine,
375(16), 1552–1565.
5.
Sahlı, E., & Gündüz, K. (2017). Thyroid-associated
Ophthalmopathy. Türk Oftalmoloji Dergisi, 47(2),
94–105.
6.
Mendoza, C., & Lacourt, P. (2015). Orbitopatía
de Graves en pediatría. Revista Médica de Chile,
143(8), 1034–1041.
7.
Bartalena, L., Marcocci, C., & Pinchera, A. (2002).
Graves’ ophthalmopathy: a preventable disease?
European Journal of Endocrinology, 146(4),
457–461.
8.
Marcocci, C., & Marinò, M. (2012). Treatment
of mild, moderate-to-severe and very severe
Graves’ orbitopathy. Best Practice & Research
Clinical Endocrinology & Metabolism, 26(3),
325–337.
9.
Baldeschi, L., Dickinson, A., Eckstein, A.,
Kendall-Taylor, P., Marcocci, C., … Wiersinga, W.
M. (2008). Consensus statement of the European
Group on Graves’ orbitopathy (EUGOGO) on
management of GO. European Journal of
Endocrinology, 158(3), 273–285.
10.
Ferreira, C., Meireles, C., Marques, O., &
Antunes, A. (2017). Therapeutic challenge
of a paediatric case of Graves’ disease with
severe ophthalmopathy. BMJ Case Reports,
bcr2017219269.
11.
Papp, A., Vasserot-Merle, C., Dorner, G., &
Paridaens, D. (2016). Severe pediatric Graves
orbitopathy in adolescents of African origin.
Orbit, 35(6), 317–320.
12.
Sadeghi, Y., Obéric, A., Theintz, G., & Hamédani,
M. (2017). Gravesʼ Ophthalmopathy in a
Paediatric Population. Klinische Monatsblätter
für Augenheilkunde, 234(04), 591–594.
13.
Lai, A., Sassi, L., Compri, E., Marino, F., Sivelli,
P., Piantanida, E., … Bartalena, L. (2010).
Lower Dose Prednisone Prevents Radioiodine-
Associated Exacerbation of Initially Mild or
Absent Graves’ Orbitopathy: A Retrospective
Cohort Study. The Journal of Clinical
Endocrinology & Metabolism, 95(3), 1333–1337
14.
Novaes, P., Diniz Grisolia, A. B., & Smith,
T. J. (2016). Update on thyroid-associated
Ophthalmopathy with a special emphasis
on the ocular surface. Clinical Diabetes and
Endocrinology, 2(1).
15.
Bartley, G. B. (2011). Rundle and His Curve.
Archives of Ophthalmology, 129(3), 356.
16.
Bartley, G. B., Fatourechi, V., Kadrmas, E. F.,
Jacobsen, S. J., Ilstrup, D. M., Garrity, J. A.,
& Gorman, C. A. (1996). Clinical features of
Graves’ ophthalmopathy in an incidence cohort.
American Journal of Ophthalmology, 121(3),
284–290.
17.
Szczapa-Jagustyn, J., Gotz-Więckowska, A.,
& Kociecki, J. (2016). An update on thyroid-
associated ophthalmopathy in children and
adolescents. Journal of Pediatric Endocrinology
and Metabolism, 29(10).
18.
18. Jarusaitiene, D., Verkauskiene, R.,
Jasinskas, V., & Jankauskiene, J. (2016).
Predictive Factors of Development of Graves’
Ophthalmopathy for Patients with Juvenile
Graves’ Disease. International Journal of
Endocrinology, 2016, 1–9.
19.
Holt, H., Hunter, D. G., Smith, J., & Dagi, L.
R. (2008). Pediatric Graves’ ophthalmopathy:
The pre- and postpubertal experience.
Journal of American Association for Pediatric
Ophthalmology and Strabismus, 12(4), 357–360.
20.
Jang, S. Y., Shin, D. Y., Lee, E. J., Choi, Y. J., Lee,
S. Y., & Yoon, J. S. (2013). Correlation between
TSH Receptor Antibody Assays and Clinical
Manifestations of Graves’ Orbitopathy. Yonsei
Medical Journal, 54(4), 1033.
21.
Bartalena, L., Burch, H. B., Burman, K. D., &
Kahaly, G. J. (2016). A 2013 European survey of
clinical practice patterns in the management of
Graves’ disease. Clinical Endocrinology, 84(1),
115–120.
22.
Mourits, M. P., Prummel, M. F., Wiersinga, W.
M., & Koornneef, L. (1997). Clinical activity score
as a guide in the management of patients with
Graves’ ophthalmopathy. Clinical Endocrinology,
47(1), 9–14.
23.
Dolman, P. J., & Rootman, J. (2006). VISA
Classification for Graves Orbitopathy: Ophthalmic
Plastic & Reconstructive Surgery, 22(5), 319–324.
24.
Bartalena, L., Baldeschi, L., Boboridis, K.,
Eckstein, A., Kahaly, G. J., Marcocci, C., …
(2016). The 2016 European Thyroid Association/
European Group on Graves’ Orbitopathy
Guidelines for the Management of Graves’
Orbitopathy. European Thyroid Journal, 5(1),
9–26.
25.
Bartalena, L. (2005). Glucocorticoids for Graves’
Ophthalmopathy: How and When. The Journal
of Clinical Endocrinology & Metabolism, 90(9),
5497–5499.
26.
Ebner, R. (2004). Treatment of thyroid associated
ophthalmopathy with periocular injections of
triamcinolone. British Journal of Ophthalmology,
88(11), 1380–1386.